ITMCTR2200005603尚未招募未知
Clinical Study on Evidence-Based Evaluation of Syndrome Differentiation and Treatment by Stages of Parkinson's Disease in Cheng Menxue's Academic Experience Inherited from DING's Internal Medicine
onghua Hospital Affiliated to Shanghai University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 年龄范围
- 30 至 80（—）
- 性别
- All
入选标准
- •For mild PD:
- •1. Meet the Idiopathic Parkinson's disease diagnostic criteria revised by The Movement Disorder Society (MDS) in 2015;
- •2.Hoehn Yahr stage =2;
- •3. Age between 30 and 80, regardless of gender;
- •4. Patients who have or have not been treated with anti-Parkinson drugs can be included. For participants who are receiving anti-Parkinson treatment (levodopa preparations, dopamine agonists, monoamine oxidase inhibitors, Catechins - O - Methyl Transferase (COMT) inhibitor, anticholinergic drugs, etc.), the dosage of anti-Parkinson drug is requested to be relatively stable for at least 3 months before this clinical trial, and no plan has been made to change existing treatment in the next 3 months.
- •5. Voluntarily participate and sign informed consent.
- •For moderate PD
- •1. Meet the diagnostic criteria of Idiopathic Parkinson's disease revised by MDS in 2015.
- •2. Hoehn Yahr stage 2.5 or 3;
- •3. 30-80 years old, no gender limitation, accompanied by wearing-off phenomenon, and/or the following motor complications: peak dyskinesia, biphasic dyskinesia, dysmyotonia, on-off phenomenon;
- •4. Dosage of anti-Parkinson drug (levodopa preparations, dopamine agonists, monoamine oxidase inhibitors, Catechins - O - Methyl Transferase (COMT) inhibitor, anticholinergic drugs, etc.) is requested to be relatively stable for at least 3 months before this clinical trial, and no plan has been made to change existing treatment in the next 3 months.
- •5. Voluntarily participate and sign informed consent.
- •For advanced patients
- •1. The diagnostic criteria of Idiopathic Parkinson's disease revised by MDS in 2015 were met;
- •2. Hoehn Yahr stage =4;
- •3. Age between 30 and 80, regardless of gender;
- •4. Dosage of anti-Parkinson drug (levodopa preparations, dopamine agonists, monoamine oxidase inhibitors, Catechins - O - Methyl Transferase (COMT) inhibitor, anticholinergic drugs, etc.) is requested to be relatively stable for at least 3 months before this clinical trial, and no plan has been made to change existing treatment in the next 3 months.
- •5. Voluntarily participate and sign informed consent.
排除标准
- •For mild PD:
- •1. Patients with Parkinson Syndrome (PS) or Parkinsonism-Plus syndrome (PPS);
- •2. Active depression or psychosis and/or under antidepressant or antipsychotic medication;
- •3. Severe sequelae of stroke and other systemic diseases such as heart, lung, liver and kidney;
- •4. History of drug or alcohol abuse;
- •5. Being participating in other clinical studies or have participated in other clinical study within the previous 30 days.
- •For moderate PD
- •1. Patients with PS or PPS;
- •2. Pregnant or lactating women, history of drug or alcohol abuse;
- •3. Severe Cognitive impairment (Montreal Cognitive Assessment scale (MoCA)<20points), active depression or psychosis and/or under antidepressant or antipsychotic medication, severe sequelae of stroke and other systemic diseases such as heart, lung, liver and kidney;
- •5. Being participating in other clinical studies or have participated in other clinical study within the previous 30 days.
- •For advanced PD
- •1. Patients with PS or PPS;
- •2. Pregnant or lactating women, history of drug abuse or alcohol abuse;
- •3. Severe cognitive impairment (MoCA< 20 points), active depression or psychosis and/or under antidepressant or antipsychotic medication, severe sequelae of severe stroke and other systemic diseases such as heart, lung, liver and kidney;
- •5. Being participating in other clinical studies or have participated in other clinical study within the previous 30 days.
研究者
相似试验
招募中
不适用
Clinical evaluation and mechanism study on the synergistic treatment and rehabilitation of diabetic macular edema by Chinese and Western medicinediabetic macular edemaITMCTR2022000026Eye Hospital, China Academy of Chinese Medical Sciences
招募中
1 期
A randomized controlled trial for Zhongfeng Xingnaoyie decoction in the treatment of Acute Cerebral InfarctioCerebral InfarctionITMCTR2100004506Hospital of Chengdu University of Traditional Chinese Medicine
尚未招募
2 期
Effect of the test product in reducing dark spotsCTRI/2024/03/064874Hindustan Unilever Limited
进行中（未招募）
4 期
A study to evaluate the efficacy of Madhuyashti,Khadira and Shankha Bhasma on AcidityCTRI/2018/05/013941Rajiv Gandhi Govt Post Graduate Ayurvedic College and Hospital
尚未招募
3 期
Clinical evaluation of Tangzu granule in the treatment of high-risk foot of diabetesHigh risk foot of diabetesITMCTR2200006534Hospital of Chengdu University of TCM